New combo therapy shows promise for tough lung cancer cases

NCT ID NCT00596648

Completed Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called cabozantinib, either alone or with another drug (erlotinib), in 92 people with advanced non-small cell lung cancer whose cancer had worsened after erlotinib treatment. The goal was to find a safe dose and see if the combination could shrink tumors. This is a disease control study, not a cure, as ongoing management is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Case Western Reserve University

Cleveland, Ohio, 44106, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Georgetown University/Lombardi Comprehensive Cancer Center

Washington D.C., District of Columbia, 20007, United States
Katmai Oncology Group

Anchorage, Alaska, 99508, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Park Nicollet Institute

Saint Louis Park, Minnesota, 55416, United States
Stanford University Medical Center

Palo Alto, California, 94305, United States
Summit Medical Group

Berkeley Heights, New Jersey, 07922, United States
Swedish Cancer Institute

Seattle, Washington, 98104, United States
University of California, Davis

Sacramento, California, 95817, United States
University of Chicago Medical Center

Chicago, Illinois, 60637, United States
University of Washington/ Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States
Yale University School of Medicine

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.